With the approval of poly (ADP-ribose) polymerase inhibitors (PARPi)12–16 for patients with pathogenic germline variants in BRCA1 and BRCA2, the NCCN recommended universal BRCA1/2 germline testing for patients with advanced ovarian and breast cancer as well as expanded homologous recombination repair (HRR) gene testing for prostate cancer17–19. This evidence concerns the gene BRCA1 and breast cancer.